X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Vector Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 30, 2024
Details:
Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Vector Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 27, 2024
Details:
Pepaxto (melphalan flufenamide, also called melflufen) is indicated in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxto
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2022
Details:
Pepaxti (melphalan flufenamide, also called melflufen) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively is delivering cytotoxic agents into tumor cells.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxto
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: European Investment Bank
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 25, 2022
Details:
Pepaxti® (melphalan flufenamide, also called melflufen) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively is delivering cytotoxic agents into tumor cells. The drug is composed of a di-peptide and an alkylating moiety.
Lead Product(s): Melphalan Flufenamide,Daratumumab
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Pepaxti (melphalan flufenamide, also called melflufen) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively is delivering cytotoxic agents into tumor cells.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
Pepaxti (melphalan flufenamide, also called melflufen) is a lipophilic peptide conjugated alkylating drug that rapidly and selectively is delivering cytotoxic agents into tumor cells.
Lead Product(s): Melphalan Flufenamide
Therapeutic Area: Oncology Product Name: Pepaxti
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2022
Details:
The first drug coming from the PDC platform, Pepaxto® (INN melphalan flufenamide), also called melflufen was granted accelerated approval in the U.S. Oncopeptides has discontinued the marketing of Pepaxto in the US and does not intend to market Pepaxto in the US at this time.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Pepaxto
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2022
Details:
The OCEAN Phase 3 results demonstrate that melflufen (Melphalan Flufenamide) improves PFS for lenalidomide refractory RRMM patients who have received two to four prior lines of therapy with significant statistical interactions between the OS HR result.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2022
Details:
Melflufen (melphalan flufenamide) a novel class of peptidase-enhanced compounds that elicit increased cytotoxicity in target multiple myeloma cells and substantially reduced off-target cell toxicity.
Lead Product(s): Melphalan Flufenamide,Dexamethasone
Therapeutic Area: Oncology Product Name: Melflufen
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
